GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nexien BioPharma Inc (OTCPK:NXEN) » Definitions » Liabilities-to-Assets

Nexien BioPharma (Nexien BioPharma) Liabilities-to-Assets : 24.29 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Nexien BioPharma Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Nexien BioPharma's Total Liabilities for the quarter that ended in Mar. 2024 was $0.34 Mil. Nexien BioPharma's Total Assets for the quarter that ended in Mar. 2024 was $0.01 Mil. Therefore, Nexien BioPharma's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 was 24.29.


Nexien BioPharma Liabilities-to-Assets Historical Data

The historical data trend for Nexien BioPharma's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nexien BioPharma Liabilities-to-Assets Chart

Nexien BioPharma Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Liabilities-to-Assets
Get a 7-Day Free Trial 0.15 1.26 1.50 1.94 6.86

Nexien BioPharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.97 6.86 14.23 105.67 24.29

Competitive Comparison of Nexien BioPharma's Liabilities-to-Assets

For the Drug Manufacturers - Specialty & Generic subindustry, Nexien BioPharma's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nexien BioPharma's Liabilities-to-Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nexien BioPharma's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Nexien BioPharma's Liabilities-to-Assets falls into.



Nexien BioPharma Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Nexien BioPharma's Liabilities-to-Assets Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Liabilities-to-Assets (A: Jun. 2023 )=Total Liabilities/Total Assets
=0.295/0.043
=6.86

Nexien BioPharma's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 is calculated as

Liabilities-to-Assets (Q: Mar. 2024 )=Total Liabilities/Total Assets
=0.34/0.014
=24.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nexien BioPharma  (OTCPK:NXEN) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Nexien BioPharma Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Nexien BioPharma's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Nexien BioPharma (Nexien BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
4340 East Kentucky Avenue, Suite 206, Glendale, CO, USA, 80246
Nexien BioPharma Inc is a researcher and developer of cannabinoid-based pharmaceutical for various medical conditions and disorders, all under U.S. Food and Drug Administration development pathways.
Executives
Jeffrey Friedland other: Former 10% Owner 4340 E KENTUCKY AVE, SUITE 206, GLENDALE CO 80246
Kanativa Usa Inc. 10 percent owner 4340 E KENTUCKY AVE, SUITE 206, GLENDALE CO 80246
Kanativa Inc. 10 percent owner 4340 E. KENTUCKY AVE., SUITE 206, GLENDALE CO 80246
Joseph F Aceto officer: VP Legal & IP Counsel 1617 NEWARK ROAD, KENNETT SQUARE PA 19348
Jeremy Robert Reeh officer: VP Translational Research 11 TANKARD LANE, WASHINGTON CROSSING PA 18977
Alexander Michael Wasyl director, officer: Chief Executive Officer 31 BEIDLER DRIVE, WASHINGTON CROSSING PA 18977
Frank J Manganella officer: VP Corporate Development 148-26 10TH AVENUE, WHITESTONE NY 11357
Clark Courtney Lynne director PO BOX 7801, ASPEN CO 81612
Lindy Snider director 408 BARBARA LANE, BRYN MAWR PA 19010
Robert I Goldfarb officer: Chief Operating Officer 230 GOLDEN BEACH DRIVE, GOLDEN BEACH FL 33160
Evan L Wasoff officer: Chief Financial Officer 101 WINGER DRIVE, NEDERLAND CO 80466
Alain D Bankier director 150 COLUMBUS AVENUE APT 17F, NEW YORK NY 10023
Richard S Greenberg director, 10 percent owner 4340 E KENTUCKY AVE, SUITE 206, GLENDALE CO 80246
Ivo Heiden director, 10 percent owner 2275 HUNTINGTON DRIVE, SUITE 851, SAN MARINO CA 91108